The Bitter Peel Behind Treatt’s Half-Year Results
When a flavour specialist like Treatt serves up a 59.6% drop in pre-tax profits, investors’ taste buds understandably twitch. Let’s unpack this citrus-scented conundrum and see what’s really brewing in the vat.
Financial Snapshot: Squeezed Margins & Strategic Lemonade
The numbers make tart reading:
- Revenue down 11% to £64.2m
- Adjusted EBITDA halved to £6.5m
- Gross margin eroded by 290 basis points
Yet amidst this squeeze, management’s holding firm on the 2.60p dividend and £5m buyback programme – a clear signal they’re not abandoning the cocktail shaker just yet.
Three Forces Shaping the Squeeze
1. The Citrus Conundrum
With citrus prices at sustained highs, customers are:
- Reformulating recipes (goodbye premium orange oil, hello budget alternatives)
- Running lean inventories
- Pushing Treatt’s R&D teams to find workarounds
2. American Jitters
North America – responsible for 41% of sales – saw consumer confidence wobble under geopolitical tensions. The result? Softening demand across premium categories that typically deliver Treatt’s juiciest margins.
3. Strategic Investments Biting
That new regional structure and Shanghai innovation centre (opening late 2025) aren’t free. Administrative expenses crept up 2.7% despite management’s “self-help” efficiency drives.
Sunny Patches in the Orchard
Not all segments are wilting:
- Treattzest: Up 43.9% as sugar-reduction trends bite
- China: Steady 1.9% growth with H2 acceleration expected
- Rest of World: 25.8% surge showing geographic diversification paying off
The CEO’s Flavour Forecast
David Shannon’s commentary mixes realism with R&D optimism:
“We’re doubling down on sugar reduction… our flavour-first, clean-label solutions are now being adopted more widely across categories like flavoured waters, energy drinks, and functional beverages.”
Translation: Treatt’s betting big on being the Willy Wonka of wellness trends.
Looking Ahead: A Palate Cleanser?
Management’s sticking to April’s revised guidance:
- FY25 revenue: £146m-£153m
- PBTE: £16m-£18m
With H2 sales already 50% covered and “exciting wins” in sugar reduction, there’s potential for upside. But watch those citrus markets – they remain the zesty wildcard.
Bottom Line: A Stock for the Patient Mixologist
Treatt’s story remains one of long-term structural trends (healthier consumption, premiumisation) versus short-term commodity wobbles. The maintained dividend and buyback suggest confidence in their recipe – but investors might want to wait for H2’s first tangible results from those strategic investments before topping up their glasses.
